MetaVia (MTVA) Non-Current Deferred Tax Liability (2015 - 2023)

MetaVia's (MTVA) quarterly Non-Current Deferred Tax Liability came in at $50000.0 in Q4 2023, up 400.0% on a QoQ basis from $10000.0 in Q4 2016.

MetaVia (MTVA) Non-Current Deferred Tax Liability (2015 - 2023) Analysis & Trends

MetaVia (MTVA) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $50000.0 in Q4 2023.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $50000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $50000.0 (changed N/A YoY) and the FY2023 annual result came in at $50000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability climbed to $50000.0 in Q4 2023, from $10000.0 in the prior quarter.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $50000.0 in Q4 2023 to a low of $50000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	MetaVia	8.72 Mn	-3.92 Mn	-

Download Data